

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.133USC1	Application Number: 09/373,403
	Applicant: ARATHOON ET AL.	
	Filing Date: AUGUST 12, 1999	Group Art Unit: 1642
	Customer No. 23552	




U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AZH	5,807,706	09/15/1998	CARTER ET AL.			
AZH	5,821,333	10/13/1998	CARTER ET AL.			

FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES NO


OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AZH		Bedzyk et al., "Active Site Structure and Antigen Binding Properties of Idiotypically Cross-reactive Anti-fluorescein Monoclonal Antibodies", <u>The Journal of Biological Chemistry</u> , 265(1):133-138 (1990)
		Bryunck, A. et al., "Characterisation of a humanized bispecific monoclonal antibody for cancer therapy", <u>Br. J. Cancer</u> , 67:436-440 (1993)
		Carter, P. et al., "Toward The Production of Bispecific Antibody Fragments for Clinical Applications", <u>J. Hematotherapy</u> , 4(5):463-470 (Oct. 1995)
		Carter, P. et al., "Engineering antibodies for imaging and therapy", <u>Curr. Opin. Biotechnology</u> , 8(4):449-454 (Aug. 1997)
		De Jonge, J. et al., "Production and Characterization of Bispecific Single-Chain Antibody Fragments", <u>Mol. Immunol.</u> , 32(17-18):1405-1412 (Dec. 1995)
		Goddard et al., NCBI Genbank AF048774 (1998)
		Goddard et al., NCBI Genbank AF048775 (1998)
		Gulliver, G. et al., "Conversion of an Anti-single-stranded DNA Active Site to an Anti-fluorescein Active Site through Heavy Chain Complementarity Determining Region Transplantation", <u>The Journal of Biological Chemistry</u> , 269(11):7934-7940 (1994)
		Gulliver, G. et al., "Effect of Transplantation of Antibody Heavy Chain Complementarity Determining Regions on Ligand Binding", <u>The Journal of Biological Chemistry</u> , 269(39):24040-24045 (Sept. 30, 1994)
		Kriangkum, J. et al., "Bispecific and bifunctional single chain recombinant antibodies", <u>Biomolecular Engineering</u> , 18(1):31-40 (Aug. 2001)

EXAMINER	<i>John L. Allen</i>	DATE CONSIDERED	9/4/2004
----------	----------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

FORM 1449* INFORMATION DISCLOSURE STATEMENT  IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.133USC1	Application Number: 09/373,403
	Applicant: ARATHOON ET AL.	
	Filing Date: AUGUST 12, 1999	Group Art Unit: 1642
	Customer No. 23552	

Alt		Mallender, W. et al., "Comparative Properties of the Single Chain Antibody and Fv Derivatives of mAb 4-4-20", <u>The Journal of Biological Chemistry</u> , 271(10):5338-5346 (March 8, 1996)
		Mallender, W. et al., "Construction, Expression, and Activity of a Bivalent Bispecific Single-chain Antibody", <u>The Journal of Biological Chemistry</u> , 269(1):199-206 (Jan. 7, 1994)
		Massino et al., "Quantitative analysis of the products of IgG chain recombination in hybrid hybridomas based on affinity chromatography and radioimmunoassay", <u>Journal of Immunological Methods</u> , 201:57-66 (1997)
		Merchant et al., "An efficient route to human bispecific IgG", <u>Nature Biotechnology</u> , 16:677-681 (July 1998)
		Muller, KM et al., "The first constant domain (C _H 1 and C _L) of an antibody used as heterodimerization domain for bispecific miniantibodies", <u>FEBS Letter</u> , 422(2):259-264 (January 30, 1998)
		Muller, KM et al., "A dimeric bispecific miniantibody combines two specificities with avidity", <u>FEBS Letter</u> , 432(1-2):45-49 (July 31, 1998)
		Pluckthun, A. et al., "New protein engineering approaches to multivalent and bispecific antibody fragments", <u>Immunotechnology</u> , 3(2):83-105 (June 1997)
		Reddy, V. et al., "Production of Hybrids Secreting Bispecific Antibodies Recognising CEA and Doxorubicin", <u>Anticancer Research</u> , 13:2077-2084 (1993)
		Rudikoff, S., "Single amino acid substitution altering antigen-binding specificity", <u>Immunology</u> , 79:1979-1983 (1982)
		Segal, DM et al., "Introduction: bispecific antibodies", <u>J. Immunol. Methods</u> , 248(1-2):1-6 (Feb. 1, 2001)
		Smith et al., "Variable Region Primary Structures of Monoclonal Anti-DNA Autoantibodies from NZB/NZW F ₁ Mice", <u>Molecular Immunology</u> , 27(5):463-470 (1990)
		Tomlinson, IM et al., "The structural repertoire of the human V _K domain", <u>EMBO Journal</u> , 14(18):4628-4638 (Sept. 15, 1995)
		Tomlinson, I. et al., "Methods for Generating Multivalent and Bispecific Antibody Fragments", <u>Methods Enzymol.</u> , 326:461-479 (2000)
		Tso, JY et al., "Preparation of a Bispecific F(ab') ₂ Targeted to the Human IL-2 Receptor", <u>J. Hematotherapy</u> , 4(5):389-394 (Oct. 1995)
✓		Vuillez, J. et al., "Two-Step Immunoscintigraphy for Non-Small-Cell Lung Cancer Staging Using a Bispecific Anti-CEA/Anti-Indium-DTPA Antibody and an Indium-111-Labeled DTPA Dimer", <u>The Journal of Nuclear Medicine</u> , 38(4):507-511 (April 1997)

EXAMINER 	DATE CONSIDERED 9/4/2003
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	